| Literature DB >> 27734022 |
Simon Faissner1, Carsten Lukas1, Anke Reinacher-Schick1, Andrea Tannapfel1, Ralf Gold1, Ingo Kleiter1.
Abstract
Entities:
Year: 2016 PMID: 27734022 PMCID: PMC5042103 DOI: 10.1212/NXI.0000000000000285
Source DB: PubMed Journal: Neurol Neuroimmunol Neuroinflamm ISSN: 2332-7812
FigureClinical and diagnostic features of a 44-year-old woman with amphiphysin-positive paraneoplastic myelitis and stiff-person syndrome (SPS)
(A) MRI performed in October 2012 shows a longitudinally extensive transverse myelitis extending from C2 to C7 (sagittal STIR and axial T2-weighted on the level of C2/3). Follow-up MRI performed in January 2015 reveals progressive atrophy of the cervical spinal cord (sagittal and axial T2-weighted). (B) Anti-amphiphysin 1 immunoglobulin (Ig) G titers as 1:x and therapies performed. At 2 time points, data of a cell-based assay (CBA) were available. (C–F) Histology of an axillar lymph node metastasis shows a typical expression profile for a poorly differentiated breast adenocarcinoma. Scale bar = 100 μM. (C) Hematoxylin & eosin. (D) Estrogen receptor. (E) Progesterone receptor. (F) GATA3. AT = apheresis therapy; GLAT = glatiramer acetate; IFT = immunofluorescence test; mPsl = methylprednisolone; NAT = natalizumab.